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tients have grossly elevated tHcy levels, but that the absoluteHyperhomocysteinemia, nutritional status, and cardiovascular
level appears to be dependent on nutritional status, proteindisease in hemodialysis patients.
intake, and SAlb. The results also suggest that the lower tHcyBackground. Hyperhomocysteinemia, cardiovascular disease
levels in patients with CVD than in those without CVD may(CVD), and malnutrition are common in patients with end-
be related to the higher prevalence of malnutrition and hypoal-stage renal disease (ESRD). This study was designed to assess
buminemia in the CVD patients. This is also in accordancepossible relationships between total plasma homocysteine
with our observation that the patients with lower tHcy had a(tHcy), nutritional status, and ischemic CVD.
worse survival rate than those with higher tHcy, consideringMethods. We performed a cross-sectional study in 117 unse-
that malnutrition is a strong risk factor for mortality and thatlected patients on maintenance hemodialysis (HD) treatment,
CVD is the most common cause of death in ESRD patients.among whom there was a high prevalence of malnutrition (56%),
as assessed by the subjective global nutritional assessment
(SGNA), and a high prevalence of CVD (60%), and prospec-
tively, we followed-up the overall mortality for four years. Hyperhomocysteinemia is considered an independentResults. The level of tHcy was elevated in 95% of the HD
risk factor for atherosclerosis in the general populationpatients, and that of total plasma cysteine (tCys) was also
[1, 2]. However, the relationship between hyperhomo-significantly elevated, while the plasma concentrations of me-
thionine (Met), serine (Ser), and taurine (Tau) were signifi- cysteinemia and vascular events is complex and not well
cantly lower than those in healthy controls. The 65 patients understood, and it is not clear why a high level of plasma
who were malnourished according to the SGNA score had total homocysteine (tHcy) appears to promote athero-significantly lower levels of serum albumin (SAlb), plasma IFG-1 sclerosis. Experimental studies suggest that homocysteine(p-IGF-1), tHcy, tCys, and Met than the 52 patients with normal
may enhance lipoprotein oxidation, increases smoothnutritional status, whereas the levels of Ser, Tau, plasma folate,
and vitamin B12 were similar in the two groups. The prevalence muscle cell proliferation, induces endothelial dysfunc-
of malnutrition was 30% in the 47 patients without CVD and tion, induces endothelial activation of factor V, and re-
was significantly higher (70%, P , 0.001) in the 70 patients duces protein C activation by arterial and venous endo-with CVD, who also had lower tHcy, SAlb, plasma IGF-1, serum thelial cells [3].creatinine (SCr), and blood hemoglobin. The tHcy levels were
The risk of premature and progressive occlusive vascu-positively correlated with SAlb, Met, tCys, and SCr. Stepwise,
multiple-regression analysis showed that tCys, SAlb, and normal- lar disease is high in chronic uremic patients and accounts
ized protein equivalent of nitrogen appearance (nPNA), an for more than 40% of the deaths in dialysis patients
indicator of protein intake, were independent predictors of [4]. The mechanism is unclear, although hypertension,tHcy. The patients with tHcy ,24 mmol/L (median value) had
disorders of lipid metabolism, glucose intolerance, smok-a significantly worse four-year survival than those with a higher
ing, and anemia, as well as inflammation/infection, maytHcy ($24 mmol/L).
Conclusions. Our results demonstrate that most of HD pa- be relevant [4, 5]. In addition, malnutrition in uremic
patients may be a predisposing factor to cardiac disease
or may contribute to a poor prognosis by aggravating
1These authors share equal responsibility for this article. pre-existing heart failure [5]. It is now well established
that uremic patients have a high prevalence of hyperho-Key words: end-stage renal disease, cardiovascular disease, hemodialy-
sis, malnutrition, protein intake, serum albumin, homocysteine. mocysteinemia. An interaction between hyperhomocys-
teinemia, hyperfibrinogenemia, and lipoprotein (a) ex-Received for publication February 24, 1999
cess has been thought to promote atherothrombosis andand in revised form October 7, 1999
Accepted for publication November 1, 1999 may contribute to the high incidence of CVD in mainte-
nance dialysis patients [6].Ó 2000 by the International Society of Nephrology
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The aim of this cross-sectional study was to analyze of water-soluble vitamins, including l-pyridoxine chlo-
ride (10 mg daily) but not folic acid or vitamin B12.plasma sulfur amino acids (sAA) in hemodialysis (HD)
patients with normal nutritional status, malnourished Thirty-five healthy subjects (23 male and 12 female),
aged 38 (21 to 64) years, were subjected to comparativeHD patients, and healthy subjects and to assess, in the
HD patients, the relationship between tHcy levels, nutri- analysis of nutritional parameters and amino acids, in-
cluding tHcy.tional status, and CVD. The HD patients were then fol-
lowed over a four-year period to assess the overall mortal- The Ethics Committee of the Karolinska Institute at
Huddinge University Hospital (Stockholm, Sweden) ap-ity in relationship to basal tHcy levels. A preliminary
report of our findings that chronic renal failure patients proved the protocol of the study, and informed consent
was obtained from each HD patient and healthy subject.with cardiovascular disease (CVD) had a lower tHcy
level than patients without CVD was presented at the
Subjective global nutritional assessmentAnnual Meeting of the American Society of Nephrology
(abstract; Suliman et al, J Am Soc Nephrol 7:1325, 1996). Subjective global nutritional assessment (SGNA) was
used to evaluate the overall protein-energy nutritional
status [9–11]. SGNA includes six subjective assessments,
METHODS three based on the patient’s history of weight loss, inci-
Subjects dence of anorexia, and incidence of vomiting, and three
based on the physician’s grading of muscle wasting, pres-It was our intention that all HD patients at dialysis
ence of edema, and loss of subcutaneous fat. These vari-centers affiliated with Huddinge University Hospital
ables were graded as: 1 5 none, 2 5 mild, 3 5 moderate,should participate in a cross-sectional study of nutritional
and 4 5 severe. The sum of the respective scores ofstatus, as previously reported [7]. Of the 128 patients
the six subjective assessments was considered to be anwho agreed to participate, plasma samples for determi-
ordinal variable in the statistical analysis. We dividednations of Hcy and other related amino acids were ob-
the patients into two groups according to the SGNAtained in 117 patients (71 male and 46 female) aged 65
score. Patients with an ordinal SGNA score between six(26 to 85) years. The causes of renal failure in the 117
and eight were placed in group I (normal nutritionalpatients included diabetic nephropathy (N 5 23), chronic
status), and those with an ordinal SGNA score equal toglomerulonephritis (N 5 34), polycystic kidney disease
or more than nine were placed in group II (mild to severe(N 5 11), pyelonephritis and interstitial nephritis (N 5
malnutrition).12), and other unspecified diseases or unknown causes
(N 5 37). Thirteen of the diabetic patients were insulin
Anthropometric measurementsdependent. Fifty-seven patients had ischemic CVD
(ICVD) at the time of entering the study; that is, they Anthropometric and dynamometer measurements were
carried out in the morning after the collection of bloodhad had one or more myocardial infarctions (N 5 18),
angina pectoris (N 5 14), aortic aneurysm (N 5 1), samples. Triceps skinfold thickness (TSF) was measured
in all subjects using the Harpenden caliper on the non-peripheral vascular diseases (N 5 18), or a history of
cerebrovascular accident (N 5 6) with neurological dominant arm in the healthy subjects and the fistula-free
arm in the HD patients. The midarm muscle circumfer-symptoms following one or more attacks of strokes.
All patients underwent electrocardiography (ECG). ence (MAMC) was derived from the TSF and midarm
circumference (MAC) as follows: MAMC 5 MAC 2Thirteen patients had chronic heart failure but did not
show clinical manifestations of ICVD or ischemic ECG (p * TSF). Hand-grip strength (HGS) was measured
using the Harpenden dynamometer. Subjects were in-changes. Eighty-six patients had no residual renal func-
tion, defined as a renal urea clearance ,0.5 mL/min. The structed to apply as much hand-grip pressure as possible,
using both hands. Dynamometry was repeated threeprotein intake was estimated by calculating the protein
equivalent of nitrogen appearance normalized to body times, and the highest score was recorded. The desirable
body weight was calculated in accordance with the pa-weight (nPNA), based on urea kinetic modeling [8].
The patients were treated with oral sodium bicarbon- tient’s height, sex, and frame-size match, using Metropol-
itan height and weight tables [12]. The individual valuesate and calcium carbonate as required to prevent acidosis
and hyperphosphatemia. Forty patients were treated for anthropometric variables (TSF, MAMC, and HGS)
were normalized by converting them to a percentage ofwith antihypertensive drugs such as angiotensin-con-
verting enzyme inhibitors, b blockers, and calcium block- the mean values of healthy subjects for the same sex.
The SGNA and the anthropometric measurements wereers. Fifteen patients with residual renal function were
treated with high doses of furosemide (250 to 500 mg/ made by one investigator (A.R.Q.) who had experience
with these methods. He was not aware of the biochemicalday). Recombinant human erythropoietin was given to
66 patients. All patients were given routine supplements data at the time of examination.
Suliman et al: Homocysteine, CVD, and malnutrition in HD 1729
Table 2. Plasma sulfur amino acid and plasma serine concentrationsTable 1. Clinical, anthropometric and biochemical data (fasting,
dialysis-free day) in hemodialysis patients (mmol/L; mean6SD) in 117 hemodialysis patients, divided into
two groups as in Table 1, and 35 healthy subjects (HS)
Group I Group II
N 5 52 N 5 65 HS Group I Group II
N 5 35 N 5 52 N 5 65
Sex, male/female 37/15 34/31
Age, years (median and range) 56 (26–79) 66 (33–85)c Methionine 33.169.9a 23.465.3 20.766.1c
Homocysteine (total) 8.961.9a 31.2615.3 24.1611.6cDiabetes, N (%) 5 (10%) 18 (28%)
CVD, N (%) 19 (36%) 51 (78%) Cysteine (total) 315.2658.0a 433.26115.1 376.86125.5b
Taurine 49.6613.5a 41.2618.4 41.5620.1Body mass index kg/m2 23.864.1 21.163.7
% Desirable body weighta 105616 90614c Serine 122.3628.8a 83.2617.6 85.6621.3
% Triceps skinfold thicknessb 115651 73637c Significant differences between all patients and controls are aP , 0.001, and
% Mid-arm muscle circumferenceb 10069 90611c between groups I and II, bP , 0.05 and cP , 0.01
% Hand-grip strengthb 71627 47620c
Serum albumin g/L 3563 3265c
Serum creatinine lmol/L 7396188 6286211
Serum urea mmol/L 18.264.9 19.766.9
Standard bicarbonate mmol/L 2462 2463 variables that independently predicted tHcy levels. Sur-
Serum C-reactive protein mg/L 19619 24623
vival analysis was carried out using the Kaplan–MeierPlasma IGF-1 ng/mL 204697 147693c
Plasma folate nmol/L 15.564.9 17.866.8 method. The data were censored for renal transplanta-
Plasma B12 pmol/L 4166141 4266161 tion. All values are expressed as mean 6 SD, unlessSerum cholesterol mmol/L 5.761.3 5.461.5
Serum triglycerides mmol/L 1.760.8 1.460.6 otherwise indicated.
nPNA g/kg/day 1.1360.23 1.0760.23
Data are mean 6 SD. Abbreviations are: CVD, cardiovascular disease; nPNA,
normalized protein equivalent of nitrogen appearance. RESULTSaThe assessment % desirable body weight was based on medium frame-size
individuals [12] Fifty-two HD patients (44%) had a normal nutritionalbExpressed as % of values in the HS of the same sex
cSignificant differences between groups I and II, P , 0.05 status (group I), and 65 patients (56%) were mildly to
severely malnourished (group II), based on SGNA (Ta-
ble 1). The distribution of primary causes of renal failure
was essentially similar in the two groups of HD patients,Biochemical analyses
except for a higher frequency of diabetes mellitus in
Venous blood samples from HD patients and control group II (N 5 18) than in group I (N 5 5). CVD was
subjects were collected in the morning after an overnight present in 60% of all the patients and in 78% of the
fast. The HD patients were investigated on a midweek, malnourished patients. The duration of HD treatment
dialysis-free day. As previously described, plasma-free was significantly (P 5 0.03) longer in group I, 25 months
amino acid concentrations [13] and tHcy and plasma
(range, 0.5 to 317 months) versus 14 months (range, 0.5
total cysteine (tCys) concentrations [14] were deter-
to 88 months) in group II. As expected, the malnourished
mined with high-performance liquid chromatography.
patients were older and had a lower percentage of desir-Serum albumin (SAlb), serum creatinine (SCr), blood urea, able body weight, MAC, TSF, HGS, SAlb, and plasmaserum C-reactive protein (SCRP), and plasma insulin-like IGF-1 (Table 1) than the well-nourished patients. Thegrowth factor-1 (IGF-1) were determined as prescribed
mean values of nPNA, plasma folate, and plasma vitaminearlier [7]. Plasma folate concentration was determined
B12 concentrations were similar in the two patient groups.with the Dualcount SPNB (solid phase no boil) radioim-
Table 2 shows that the tHcy and tCys were significantlymunoassay kit from Diagnostic Product Corporation
higher in the patient groups than in healthy subjects,(Los Angeles, CA, USA).
whereas plasma methionine (Met), plasma taurine (Tau),
and plasma serine (Ser) concentrations were lower inStatistical analyses
the HD patients. The Met, tHcy, and tCys concentrationsDifferences between the three groups were analyzed
were significantly lower in group II (malnourished) pa-by analysis of variance (ANOVA). When the ANOVA
tients than in group I. There were no significant differ-was found to be significant at P , 0.05, Dunnett’s test
ences in Tau and Ser concentrations between the twowas used to compare the differences between the healthy
patient groups.subjects and HD patient groups. Comparisons between
Hyperhomocysteinemia was present in the vast major-two groups were assessed for continuous variables by
ity of the 117 HD patients, 95% of all patients, 90% ofthe Student’s t-test, the Mann–Whitney test was used
the HD patients with CVD, and 96% of the patientswhen distribution was skewed, and for nominal variables
without CVD had tHcy levels .13 mmol/L (.95th per-by the chi-square test. Spearman’s rank correlation was
centile of the tHcy level in healthy subjects). Dividingused to determine correlations between variables. Step-
wise multiple-regression analysis was applied to identify the HD patients into two groups, based on presence of
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Table 3. Significance of differences between hemodialysis patients
with or without cardiovascular diseases
No CVD CVD P
Male/female 33/14 38/32
Age years 56616 64612 0.0025a
Prevalence of malnutrition 30% 70% 0.0001b
Total plasma homocysteine
lmol/L (all patients) 31615 24612 0.016a
Total plasma homocysteine
lmol/L (ICVD, N 5 57)d 23610 0.003
Total plasma cysteine,
lmol/L 4116128 3956120 NSa
Plasma IGF-1 ng/mL 2006111 158689 0.03c
Serum albumin g/L
(all patients) 34.564.8 32.564.5 0.01a
Serum albumin g/L
(ICVD, N 5 57)d 32.764.1 0.04a
Fig. 1. Total plasma homocysteine concentrations in hemodialysisBlood hemoglobin g/L 103615 96615 0.01a
(HD) patients with ischemic cardiovascular disease (ICVD, N 5 57)Serum creatinine lmol/L 7566211 6356192 0.007a
and in HD patients without cardiovascular disease (non-CVD, N 5Prevalence of serum C-reactive
47). Thirteen patients who had chronic heart failure without signs ofprotein .10 mg/L 51% 47% NSb
ICVD were excluded from the analysis. Symbols are: (whiskers) maxi-Plasma folate nmol/L 16.766.1 17.166.4 NSa
mum and minimum non-outliers; (h) median, 75% and 25%; (8) outliers;Plasma B12 pmol/L 4226155 4236153 NSa
(*) extremes. Difference between the groups: P 5 0.003.
aSignificance was tested with Student’s t-test
bSignificance was tested with chi-square test
cSignificance was tested with the nonparametric Mann–Whitney test
dPatients with chronic cardiac failure without signs of ischemic cardiovascular
disease (ICVD) were excluded
than the HD patients less than 65 years old (32 6 4 vs.
35 6 5 mmol/L, P , 0.001) and lower tHcy (24.5 6 8.6
vs. 28.9 6 15.3 mmol/L, P 5 0.05), as compared with the
younger patients.CVD, as shown in Table 3, we found that HD patients
A correlation matrix, presenting Spearman’s rank cor-with CVD were older and had lower SAlb levels than
relation coefficients for the HD patients, is shown inthose without CVD. The tHcy concentration was lower
Table 4. The SGNA score was negatively correlated within HD patients with CVD than in those without CVD
SAlb, SCr, tCys, tHcy, IGF-1, and Met levels, but it was(Table 3), and this difference was also present after ex-
not significantly correlated with nPNA and SCRP. Plasmacluding the 13 HD patients with chronic heart failure
tHcy was positively correlated with SAlb, tCys, and SCrwho had no signs of ischemia (Table 3 and Fig. 1). The
levels, as shown in Figure 2, and was also correlated withplasma folate and vitamin B12 concentrations were simi-
Met, but did not correlate with SCRP (Table 4), plasmalar in the two patient groups, and the concentrations of
folate (r 5 20.15, P 5 0.11), and plasma B12 (r 5 20.05,folate and B12, in all HD patients, were within the normal
P 5 0.6). Serum albumin was also positively correlatedrange [15]. The levels of plasma IGF-1, blood hemoglo-
with Met, tCys, and IGF-1, and negatively correlatedbin, and SCr were significantly lower in patients with
with SCRP. In addition, tCys was positively correlated withCVD. The proportion of patients with serum SCRP .10
Met and SCr. Normalized PNA was positively correlatedmg/L was also similar in the two groups of patients.
with Met and inversely with SCRP.There were more males among the HD patients with
Stepwise multiple-regression analysis was used to findCVD than in those without CVD (72 vs. 52%, P 5
significant independent predictors of tHcy in the HD0.03). Therefore, we also evaluated males and females
patients (Table 5). Plasma Cys (r 2 5 0.23) was the strong-separately to determine the tHcy concentration. In male
HD patients, the tHcy level was significantly lower in est predictor, followed by SAlb (r 2 5 0.11) and protein
intake (r 2 5 0.04), as assessed by nPNA. The regressionpatients with CVD than in those without (24 6 13 vs.
32 6 16 mmol/L, respectively, P 5 0.02), whereas the model could explain 38% of the variation in tHcy. Omit-
ting tCys from the model reduced the adjusted total r 2levels were not significantly different in female HD pa-
tients with or without CVD (25 6 12 vs. 28 6 11 mmol/L, from 0.38 to 0.17.
The median level of tHcy in the HD patients was 24respectively, P 5 0.5). Among the 52 male patients aged
50 years or more at the time of the study, the tHcy mmol/L. The cumulative Kaplan–Meier survival analysis
of patients with tHcy $24 mmol/L and ,24 mmol/Lconcentration in those with CVD (N 5 32) was 24.9 6
14.2 mmol/L, and in those without CVD (N 5 20), it was showed a significantly worse survival in those with lower
tHcy levels (Fig. 3). Figure 3 represents the overall mor-31.6 6 18.2 mmol/L (P 5 0.07).
The median age of the HD patients was 65 years. tality of HD patients and not only mortality caused by
cardiovascular events.Those more than 65 years of age had lower SAlb levels
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Table 4. Spearman rank correlation matrix for eight variables
Variable SGNA score SCRP p-IGF-1 nPNA SAlb SCr p-methionine p-Hcy
SCRP 0.17
p-IGF-1 20.27b 0.27b
nPNA 20.13 20.20a 0.33c
SAlb 20.42c 20.23a 0.42c 0.23a
SCr 20.32c 20.30c 0.37c 0.09 0.13
p-methionine 20.21a 20.13 0.11 0.22a 0.31c 0.05
p-Hcy 20.28b 20.18 0.07 0.12 0.39c 0.30c 0.27b
p-Cys 20.29b 20.16 0.04 0.17 0.26b 0.36c 0.24a 0.60c
Abbreviations are in the Appendix.
aP , 0.05, bP , 0.01, cP , 0.001
Fig. 2. Relationship between total plasma homocysteine and total plasma cysteine (A), serum albumin (B), and serum creatinine (C), and the
relationship between total plasma cysteine and serum albumin (D) in 117 hemodialysis patients.
DISCUSSION mans [19]. Disturbed methylation reactions caused by
uremia or cofactor (folate, vitamin B6) deficiency haveThe results of the present study demonstrate a high
also been thought to contribute to hyperhomocysteine-prevalence of hyperhomocysteinemia in HD patients,
mia [20]. Moreover, the extrarenal Hcy metabolism maythus confirming earlier reports. However, the precise
decrease because of the inhibition by retained metabo-mechanism of hyperhomocysteinemia in chronic renal
lites [21]. Supplementation with vitamins (folate, vitaminfailure remains unclear. Reduced renal excretion [16]
B6) reduces but generally fails to normalize elevated Hcyand decreased renal uptake [17, 18] of Hcy have been
levels in uremia [22].reported, but recent findings do not show that renal
elimination of Hcy is of any significance in normal hu- We observed (Table 2) that the levels of tHcy and
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Table 5. Multivariate analysis of predictors of plasma homocysteine
in 117 HD patients
Standard
Estimate error r 2 P
Intercept 226.33 7.9 0.0012
Plasma cysteine mmol/L 0.05 0.008 0.23 ,0.0001
Serum albumin g/L 1.02 0.23 0.34 ,0.0001
nPNA groups (,1.1 vs. $1.1) 2.98 1.05 0.38 0.006
CVD vs. others 21.99 1.05 0.40 0.06
Adjusted total r 2 5 0.38.
tCys were elevated and significantly correlated (Fig. 2),
and that in multifactorial analysis tCys was the strongest
predictor of tHcy. Moreover, the levels of Met (the pre-
Fig. 3. Kaplan–Meier plots of the survival rate of hemodialysis patients.cursor essential sAA) and Tau (an end-product of Met The patients were divided into two groups according to the plasma
metabolism) were low. These findings are consistent with total homocysteine level, that is, ,24 mmol/L (solid line) and $24
mmol/L (dashed line). This figure represents the overall mortality ofour previous observation in smaller groups of HD pa-
HD patients and not only mortality caused by cardiovascular events.tients [13, 22, 23]. We also reported earlier that plasma Difference between the groups: P 5 0.02.
and muscle Tau are depleted in dialysis patients [24–26]
and that the plasma levels of cysteinesulfinic acid (CSA)
are elevated [13]. We speculated earlier that inhibition
trition, based on the concept that the level of SAlb reflectsof Tau synthesis from CSA might have a role in the
the visceral protein status. However, protein intake anddevelopment of hyperhomocysteinemia in renal failure
various catabolic factors, as well as nonnutritional factorspatients [13]. However, a recent study using stable iso-
may influence SAlb [31]. Accordingly, SAlb levels may nottopes demonstrates that homocysteine remethylation
only reflect protein malnutrition [32, 33]. In this study,rather than transsulfuration is decreased in renal failure
SAlb was related to inflammation, as assessed by the SCRPpatients [27].
(inversely correlated), but no relationship was found be-
tween SCRP and tHcy (Table 4), therefore suggesting thatHomocysteine, nutritional status, and serum albumin
the relationship between tHcy and SAlb most likely wasTo investigate the relationship between tHcy levels
not due to inflammation.and nutritional status in HD patients, we divided the
In this study, the protein intake, estimated from the
patients according to the SGNA into two groups. The
nPNA, did not differ between the two groups of patients.
patients in group II (malnourished group; Table 1) had However, in a stepwise multiple-regression model, we
low SAlb and anthropometric measurements (percentage found that nPNA, an indicator of protein intake, was
of desirable body weight, fat mass, MAMC, TSF, and indeed a predictor of the tHcy level (Table 5). Moreover,
HGS), as compared with the patients in group I (well- the correlations between Met and tHcy, as well as be-
nourished group). The results of the present study show tween Met and nPNA (Table 4), may indicate that the
also that tHcy levels are consistently elevated in the HD tHcy level in HD patients was dependent on the intake
patients (95%), and this change is more marked in well- of dietary protein, which is the only source of Met. Inade-
nourished patients, whereas malnourished patients had quate concentrations of the vitamin cofactors (folate,
lower tHcy concentrations (Table 2). Thus, one factor vitamin B12 and vitamin B6) are contributing factors for
that may have directly contributed to the lower tHcy hyperhomocysteinemia. The plasma concentrations of
levels in the malnourished HD patients is the lower levels folate and B12 were within the normal range in our pa-
of SAlb. In the general population, protein-bound Hcy tients and were similar in the well-nourished and mal-
accounts for more than 65% of total Hcy [23, 28, 29] nourished patients. We did not measure vitamin B6, but
and the main Hcy carrier in plasma is SAlb [30]. In uremic our patients were routinely supplemented with pyri-
patients, the fraction of protein-bound Hcy is similar to doxine.
that in normal subjects; however, it is higher in dialyzed Age is a determinant of both the tHcy and tCys levels,
than in nondialyzed uremic patients [23]. Hence, it seems and this physiological age-related increase may be linked
likely that SAlb is a strong determinant of tHcy in HD to the age-related decrease in renal function [34]. How-
patients, and this may contribute to the low tHcy levels ever, these levels were in fact lower in our older patients,
in malnourished patients. possibly because they also had a lower SAlb than the
Serum albumin is considered a key index of nutritional younger patients, considering that tHcy and tCys are
correlated to SAlb (Table 4).status, and it is commonly used to assess protein malnu-
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Homocysteine and cardiovascular disease are interrelated [5]. Hypoalbuminemia and malnutrition
per se may be risk factors for cardiac disease, but cardiacIn the present study, the tHcy levels in HD patients
disease may also lead to malnutrition, as has been dem-were three to four times higher than in the controls,
onstrated in the general population [44]. Moreover, awith only 5% of the patients having normal tHcy levels,
common mechanism for the development of CVD andhyperhomocysteinemia being defined as .95th percen-
malnutrition might be cytokine activation associatedtile of the normal range. Assuming that hyperhomocys-
with reduced renal function or inflammation, since proin-teinemia carries an increased risk of ICVD, this implies
flammatory cytokines (interleukin-1, interleukin-6, tu-that practically all chronic HD patients are exposed to
mor necrosis factor) may suppress appetite, cause musclethis risk. This is in accordance with the high prevalence of
proteolysis and hypoalbuminemia, and may be involvedCVD in the patients in this study and in several previous
in the processes leading to atherosclerosis [5].studies. On the other hand, our patients with ICVD had
We observed that the HD patients with lower tHcysignificantly lower (although still elevated) tHcy levels
levels (,24 mmol/L) had a significantly worse survivalthan those without CVD, a finding that may seem para-
rate than those with higher levels ($24 mmol/L; Fig. 3).doxical if one assumes that hyperhomocysteinemia, in
This may seem paradoxical in view of the establishedparticular absolute tHcy levels, carry more risk for CVD.
relationship between elevated tHcy levels and increasedHowever, these observations do not exclude a role for
mortality in the general population [45], as well as inhyperhomocysteinemia, since almost all patients would
uremic patients [39–41]. However, we are aware thatbe exposed to this risk and since other factors might be
tHcy levels are influenced by various factors such aspresent that confound the relationship between tHcy
nutritional status, SAlb, and the presence of CVD, whichlevels and CVD. An interaction between hyperhomocys-
are interrelated in a complex manner and also may in-teinemia, hyperfibrinogenemia, and lipoprotein(a) ex-
fluence the overall mortality. Unfortunately, it is notcess has been suggested [6]. It is noteworthy that men
feasible to evaluate the independent effects of tHcy andwith CVD had significantly lower tHcy levels, but we
these other factors on mortality because of the limited
found no difference in tHcy levels between females with
number of patients in the present study. Interestingly, a
or without CVD. recent study by Sirrs et al also has shown that HD pa-
Conflicting findings have been reported regarding the tients with higher tHcy levels appear to have a better
association between the tHcy level and the prevalence survival rate than those with lower levels [46].
of CVD in chronic renal failure patients. In the study Since both lower tHcy levels and a higher prevalence
by Robinson et al in HD patients, risk factor analyses of CVD were associated with hypoalbuminemia and mal-
showed a significant relationship between the tHcy level nutrition, this implies that nutritional status and the SAlb
and atherosclerotic CVD, even after adjustment for concentration should be taken into consideration when
other risk factors [35]. Others have reported a similar evaluating tHcy as a risk factor. Currently, we do not
association [36–38]. Moreover, three prospective studies know whether there is a critical plasma level at which
demonstrated that a high tHcy level indeed was related Hcy becomes atherogenic in uremic patients or whether
to cardiovascular events in chronic renal failure patients there is a relationship between atherogenic effects and
[39–41]. In contrast, Bostom et al found no relationship absolute levels of Hcy above that critical level. More-
between the fasting tHcy level and prevalence of CVD in over, it is not known to what extent hyperhomocysteine-
dialyzed uremic patients, using crude or multiple logistic mia in uremic patients acts in concert with other potential
regression analyses adjusted for other risk factors [42]. risk factors for CVD, such as hypoalbuminemia, malnu-
In addition, Klusmann et al (abstract; Wien Klin Wo- trition, lipid abnormalities, inflammation, hyperfibrino-
chenschr 110:26, 1998) reported that there was no differ- genemia, and oxidative stress. Hence, the higher mortal-
ence in tHcy levels between uremic patients with coro- ity in our patients with lower (although still high) tHcy
nary artery disease and those without; however, they may be related to the higher prevalence of malnutrition,
could not identify tHcy as an independent cardiovascular lower protein intake, and lower SAlb in the HD patients
risk factor in their patients. with CVD, considering that malnutrition is a risk factor
As shown in the present study, HD patients with ICVD for mortality and that CVD is the most common cause
have a higher prevalence of malnutrition and hypoal- of death in ESRD patients.
buminemia and a lower protein intake than those without In summary, our study indicates that tCys, nutritional
ICVD. Foley et al also reported a strong relationship status, and protein intake may influence the tHcy levels
between hypoalbuminemia and CVD in end-stage renal in HD patients. A higher absolute level of plasma tHcy
disease (ESRD) patients, and suggested that hypoalbum- in HD patients appeared to be associated with a lower
inemia is an important risk factor for CVD in these prevalence of CVD and better survival, possibly related
patients [43]. However, it is not clear how cardiac disease, to increased protein intake, better nutritional status, and
a higher SAlb level. This apparently paradoxical relation-hypoalbuminemia, and malnutrition in uremic patients
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depletion and accumulation of cysteinesulfinic acid in chronic dial-ship, however, does not contradict that hyperhomocys-
ysis patients. Kidney Int 50:1713–1717, 1996
teinemia, present in 95% of the HD patients, is a risk 14. Ubbink JB, Vermaak WJH, Bissbort S: Rapid high-performance
liquid chromatographic assay for total homocysteine levels in hu-factor for CVD in uremia.
man serum. J Chromatogr 565:441–446, 1991
15. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH:
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